Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

PHASE2TerminatedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

December 18, 2024

Study Completion Date

January 16, 2025

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

Oral EP262

Once daily

DRUG

Placebo

Once daily

Trial Locations (48)

11211

Bobby Buka MD, PC, New York

12203

Institut fur Allergieforschung Charite - Universitatsmedizin Berlin, Berlin

14845

Corning Center for Clinical Research, Horseheads

15241

Allergy and Clinical Immunology Associates, Pittsburgh

21162

Chesapeake Clinical Research, Inc., White Marsh

21224

Johns Hopkins University, Baltimore

28040

Hospital Clinico San Carlos, Madrid

28803

Allergy Partners Clinical Research, Asheville

29420

National Allergy and Asthma Research, LLC., North Charleston

30625

Medizinische Hochschule Hannover, Hanover

32541

Allervie Clinical Research, Destin

33060

NuLine Clinical Trial Center, Pompano Beach

33136

University of Miami Itch Center, Miami

33186

Florida Center for Allergy and Asthma Research, Miami

33607

Advanced Clinical Research Institute, Tampa

33612

University of South Florida, Tampa

35209

AllerVie Clinical Research, Birmingham

42301

Allergy & Asthma Specialists, P.S.C., Owensboro

43617

Toledo Institute of Clinical Research Inc., Toledo

45236

Bernstein Clinical Research Center, LLC, Cincinnati

46015

Hospital Arnau de Vilanova, Valencia

46168

The Indiana Clinical Trials Center, Plainfield

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

47150

Southern Indiana Clinical Trials, New Albany

55131

Universitatsmedizin Mainz der Johannes Gutenberg-Universitat, Mainz

59808

Montana Medical Research, Inc., Missoula

63141

The Clinical Research Center LLC, St Louis

66210

Velocity Clinical Research, Overland Park, KC Asthma & Allergy, Overland Park

72205

Little Rock Allergy & Asthma Clinical Research Center, Little Rock

74136

Vital Prospects Clinical Research Institute, PC, Tulsa

78213

Progressive Clinical Research, PA, San Antonio

83706

Treasure Valley Medical Research, Boise

84107

Allergy Associates of Utah, Murray

85260

Scottsdale Clinical Trials, Scottsdale

89030

Las Vegas Clinical Trials, North Las Vegas

90025

Antelope Valley Clinical Trials, Los Angeles

92647

Allergy and Asthma Specialists Medical Group, Huntington Beach

92708

First OC Dermatology Research, Inc., Fountain Valley

02919

Clinical Partners, LLC, Johnston

K1H1E4

Red Maple Trials Inc., Ottawa

M5G 1E2

Evidence Based Medical Educator Inc, Toronto

Unknown

Centre de Recherche Saint-Louis, Québec

01307

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden

2333 CL

Centre for Human Drug Research, Leiden

02-482

Prywatna Praktyka Lekarska Ewa Ring, Warsaw

02-507

Pim Mswia, Warsaw

80-546

Centrum Badan Klinicznych PI-House Sp. z o.o., Gdansk

08003

Hospital del Mar, Barcelona

Sponsors
All Listed Sponsors
lead

Escient Pharmaceuticals, Inc

INDUSTRY

NCT06077773 - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter